Artikel: Multiple sclerosis--new treatment modalities.
The Indian journal of medical research
2016 Band 142, Heft 6, Seite(n) 647–654
Abstract: Ever since the introduction of the first disease modifying therapies, the concept of multiple sclerosis treatment algorithms developed ceaselessly. The increasing number of available drugs is paralleled by impelling issue of ensuring the most appropriate ...
Abstract | Ever since the introduction of the first disease modifying therapies, the concept of multiple sclerosis treatment algorithms developed ceaselessly. The increasing number of available drugs is paralleled by impelling issue of ensuring the most appropriate treatment to the right patient at the right time. The purpose of this review is to describe novel agents recently approved for multiple sclerosis treatment, namely teriflunomide, alemtuzumab and dimethylfumarate, focusing on mechanism of action, efficacy data in experimental setting, safety and tolerability. The place in therapy of newer treatment implies careful balancing of risk-benefit profile as well as accurate patient selection. Hence the widening of therapeutic arsenal provides greater opportunity for personalized therapy but also entails a complex trade-off between efficacy, tolerability, safety and eventually patient preference. |
---|---|
Mesh-Begriff(e) | Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Clinical Trials as Topic ; Humans ; Multiple Sclerosis/drug therapy |
Chemische Substanzen | Antibodies, Monoclonal |
Sprache | Englisch |
Erscheinungsdatum | 2016-02-01 |
Erscheinungsland | India |
Dokumenttyp | Journal Article ; Review |
ZDB-ID | 390883-5 |
ISSN | 0971-5916 ; 0019-5340 |
ISSN | 0971-5916 ; 0019-5340 |
DOI | 10.4103/0971-5916.174543 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Ua VI Zs.143: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.